• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

byZoya GomesandYuchen Dai
January 24, 2023
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized clinical trial, among 2859 patients, death occurred in 26.1% of patients randomized to torsemide and 26.2% of patients randomized to furosemide over a median follow-up period of 17.4 months, with no significant difference between groups.

2. Rates of hospitalizations in the torsemide and furosemide groups were 37.5% and 40.4%, respectively.

Evidence Rating Level:1 (Excellent)

Study Rundown: Heart failure (HF) is commonly characterized by symptoms of congestion and volume overload that can present as dyspnea and edema. Current guidelines recommend the use of diuretics for the treatment of congestion in symptomatic patients with HF. Furosemide is the most commonly prescribed diuretic for HF, however, recent clinical data suggest potential benefits of torsemide when compared when furosemide. The objective of the TRANSFORM-HF (Torsemide Comparison with Furosemide for Management of Heart Failure) trial was to compare the effectiveness of torsemide with furosemide in patients hospitalized with HF. A total of 2859 participants hospitalized with HF were recruited between 2018 and 2022, with follow-up through 30 months for death and 12 months for hospitalizations. Patients were randomized to receive either torsemide (n=1431) or furosemide (n=1428). The main outcome was all-cause mortality, and secondary outcomes included all-cause hospitalization and total hospitalizations assessed over 12 months. Death occurred in 26.1% of patients in the torsemide group, and 26.2% of patients in the furosemide group. 12 months post-randomization, all-cause mortality or all-cause hospitalization occurred in 47.3% of patients in the torsemide group and 49.3% of patients in the furosemide group. When compared with furosemide, torsemide did not result in a significant difference in all-cause mortality over 12 months.  A major strength of this trial was that over 30% women were recruited for both intervention groups. Interpretation of these findings may be limited, however, due to the loss to follow-up, participant crossover and non-adherence.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: From the change the management of patients with heart failure registry

RELATED REPORTS

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

Clinical decision-making strategy improves acute heart failure outcomes

Ferric derisomaltose may reduce heart failure-related hospitalizations

In-Depth [randomized controlled trial]: This study investigated whether torsemide resulted in decreased mortality compared with furosemide in patients hospitalized for HF. The TRANSFORM-HF trial recruited a total of 2859 patients that were randomized to receive either torsemide (n = 1431) or furosemide (n = 1428). The primary outcome was all-cause mortality, with secondary outcomes including all-cause hospitalization and total hospitalizations assessed over 12 months. Death occurred in 373 of 1431 patients (26.1%) in the torsemide group and 374 of 1428 patients (26.2%) in the furosemide group (HR, 1.02 [95% CI, 0.89-1.18]; P = .76). All-cause mortality or all-cause hospitalization occurred in 677 patients (47.3%) in the torsemide group and 704 patients (49.3%) in the furosemide group (HR, 0.92 [95% CI, 0.83-1.02]). There were 940 total hospitalizations among 536 participants (37.5%) in the torsemide group and 987 total hospitalizations among 577 participants (40.4%) in the furosemide group (rate ratio, 0.94 [95% CI, 0.84 – 1.07]). The post hoc analysis addressed competing risks for all-cause hospitalizations over a 12-month period and determined a hazard ratio of 0.88 (95% CI, 0.78 – 0.99) with torsemide compared with furosemide.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: furosemideheart failuretorsemideTRANSFORM-HF
Previous Post

#VisualAbstract: Thromboprophylaxis with aspirin is non-inferior to low-molecular-weight heparin in preventing death for patients with orthopedic trauma

Next Post

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

RelatedReports

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
StudyGraphics

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

January 27, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
No association found between length of storage for transfused red blood cells and patient mortality
Cardiology

Ferric derisomaltose may reduce heart failure-related hospitalizations

December 27, 2022
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

No known association between PCSK9 gene variants and risk of heart failure

December 22, 2022
Next Post
Long-term use of apremilast for psoriasis associated with an acceptable safety profile

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

Evidence-based supportive therapy for bronchiolitis varies significantly between hospitals

Teach-back method effective to improve postpartum maternal-infant health

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options